ArticleAmerican journal of translational research2024
Serum hsa_circ_0007534 as a diagnostic biomarker for ovarian cancer.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating circRNAs at the frontier of cancer detection, prognosis, and therapy.Chinese medical journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the implications of serum hsa_circ_0007534 levels in ovarian cancer (OC) patients.
methodsA retrospective analysis was conducted on the clinical data of 102 OC patients, and 102 healthy controls (HCs) were included in this study. Serum levels of hsa_circ_0007534 were measured using qPCR. The relationship between circRNA levels and clinicopathologic characteristics was analyzed. Additionally, the diagnostic performances of serum hsa_circ_0007534 and CA-125 levels in OC patients were evaluated using Receiver Operating Characteristic (ROC) curve analyses.
resultsOC patients had significantly elevated serum hsa_circ_0007534 levels compared to HCs, allowing a differentiation between OC patients and HCs. Higher serum hsa_circ_0007534 levels were associated with more aggressive disease features and poorer overall survival. Patients with elevated hsa_circ_0007534 levels tended to have worse clinical outcome compared to those with lower levels. Multivariate analyses indicated that high hsa_circ_0007534 levels were independently associated with poorer outcome. Furthermore, serum hsa_circ_0007534 levels effectively distinguished between chemoresistant and chemosensitive patient groups.
conclusionsSerum hsa_circ_0007534 levels may serve as valuable predictors of prognosis in OC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.